News Image

Is NASDAQ:AMPH a Fit for Growth Investing Strategies?

By Mill Chart

Last update: Feb 7, 2024

Groth investors are looking for stocks showing high revenue and EPS growth. We will have a look here to see if AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is suited for growth investing. Investors should of course do their own research, but we spotted AMPHASTAR PHARMACEUTICALS IN showing up in our CANSLIM growth screen, so it may be worth spending some more time on it.

Looking into the canslim metrics of AMPHASTAR PHARMACEUTICALS IN

  • AMPHASTAR PHARMACEUTICALS IN has shown positive momentum in its earnings per share (EPS) on a quarter-to-quarter (Q2Q) basis, with a 203.0% increase. This reflects the company's successful execution of its business strategies and its commitment to delivering improved financial results.
  • The quarter-to-quarter (Q2Q) revenue growth of 50.37% of AMPHASTAR PHARMACEUTICALS IN has been strong, reflecting the company's ability to generate consistent sales growth. This growth suggests the company's ability to meet customer needs and drive revenue growth.
  • The 3-year EPS growth of AMPHASTAR PHARMACEUTICALS IN (77.88%) highlights the company's ability to consistently improve its earnings performance and suggests a positive outlook for future profitability.
  • AMPHASTAR PHARMACEUTICALS IN has achieved an impressive Return on Equity (ROE) of 22.72%, showcasing its ability to generate favorable returns for shareholders.
  • The Relative Strength (RS) of AMPHASTAR PHARMACEUTICALS IN has been consistently solid, with a current 90.21 rating. This highlights the stock's ability to exhibit sustained price strength and signifies its competitive advantage. AMPHASTAR PHARMACEUTICALS IN exhibits strong prospects for further price appreciation.
  • Maintaining a Debt-to-Equity ratio of 1.07, AMPHASTAR PHARMACEUTICALS IN demonstrates a conservative financial approach. This signifies the company's focus on minimizing debt burdens while preserving a solid equity position.
  • The ownership composition of AMPHASTAR PHARMACEUTICALS IN reflects a balanced investor ecosystem, with institutional shareholders owning 66.67%. This indicates a broader market participation and potential for increased trading liquidity.

Deciphering the Technical Picture of NASDAQ:AMPH

ChartMill assigns a Technical Rating to every stock. This score, ranging from 0 to 10, is updated daily and is determined by evaluating multiple technical indicators and properties.

We assign a technical rating of 4 out of 10 to AMPH. Although AMPH is scoring some points because its good overall performance in the market in the past year, recent evolutions are not that positive. Both the medium and short term picture give negative signs.

  • When comparing the yearly performance of all stocks, we notice that AMPH is one of the better performing stocks in the market, outperforming 90% of all stocks. We also observe that the gains produced by AMPH over the past year are nicely spread over this period.
  • AMPH is one of the better performing stocks in the Pharmaceuticals industry, it outperforms 80% of 204 stocks in the same industry.
  • The short term trend is negative, the long term trend is neutral. Not much exciting going on here.
  • AMPH is currently trading in the middle of its 52 week range. The S&P500 Index however is currently trading near new highs, so AMPH is lagging the market.

Check the latest full technical report of AMPH for a complete technical analysis.

Fundamental Analysis Observations

Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.

AMPH gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 204 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes AMPH very considerable for value and growth investing!

Check the latest full fundamental report of AMPH for a complete fundamental analysis.

Our CANSLIM screen will find you more ideas suited for growth investing.


Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.



NASDAQ:AMPH (4/22/2024, 7:00:00 PM)

After market: 40.17 0 (0%)


+0.16 (+0.4%)


News Image4 days ago - Market News VideoOversold Conditions For Amphastar Pharmaceuticals (AMPH)
News Image10 days ago - Market News VideoCommit To Buy Amphastar Pharmaceuticals At $22.50, Earn 18.5% Annualized Using Options
News Image2 months ago - Market News VideoAmphastar Pharmaceuticals Becomes Oversold (AMPH)
News Image2 months ago - Market News VideoAmphastar Pharmaceuticals (AMPH) Shares Cross Below 200 DMA
News Image2 months ago - Seeking AlphaAmphastar Pharmaceuticals Non-GAAP EPS of $0.88 misses by $0.03, revenue of $178.1M beats by $4.77M (NASDAQ:AMPH)

Amphastar Pharmaceuticals reports Q4 financial results with a Non-GAAP EPS of $0.88, missing estimates by $0.03, while revenue of $178.1M beats expectations...

News Image2 months ago - Investor's Business DailyCRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

News Image3 months ago - Market News VideoAMPH Crosses Below Key Moving Average Level
News Image3 months ago - InvestorPlace3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential

As the new business cycle gets started, here are some biotech stocks with potential that investors should pay attention to.

News Image3 months ago - Investor's Business DailyAxsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

AMPH Links
Follow us for more